DeutschNewstral
Article
Mmarketwatch.com on 2018-08-11 16:09
Alnylam rare drug gets FDA approval, to cost $345,000 on average
Related news
- MAlnylam shares drop 1.8% on new FDA approval strategy for rare disease drugmarketwatch.com
- MAlnylam shares jump on FDA approvalmarketwatch.com
FDA gives early OK to Alnylam rare disease drugbizjournals.com- MCelgene's rare disease drug gets FDA approvalmarketwatch.com
- Shire wins FDA approval for potential blockbuster rare disease drugbizjournals.com
FDA grants 23andMe approval to test for rare genetic conditionThe Verge- EMD Serono nabs FDA approval for rare skin cancer drugbizjournals.com
Leadiant gets FDA approval for treatment for rare diseasethedailyrecord.com
Alnylam Touts Positive Data On Second Drug, Plans FDA MeetingForbes- MBioMarin shares rise on FDA approval of rare metabolic disorder drugmarketwatch.com
23andMe gets FDA approval, but only to test rare Bloom syndromeengadget- Biogen loses edge on blockbuster rare disease market with Novartis' FDA approvalbizjournals.com
FDA Grants 23andMe Approval to Sell Test for a Rare Genetic Conditiongizmodo.com- MUruGen shares jump 10% on FDA approval of rare cancer treatmentmarketwatch.com
- MUroGen shares jump 10% on FDA approval of rare cancer treatmentmarketwatch.com
- Vanda steps closer to potential FDA approval for rare developmental disorder treatmentbizjournals.com
- MFDA grants a second approval to Ultragenyx drug for rare diseasemarketwatch.com
- Vanda drug wins FDA approval for sleep disturbance in rare developmental disorderbizjournals.com
- Alnylam releases promising data on rare disease drugbizjournals.com
- Wilmington-based Incyte receives FDA approval for therapy to treat a rare cancerbizjournals.com